{"entity":{"id":"bba401c5-eaa6-57ec-9730-e5eeb88b37f1","name":"DEERFIELD PRIVATE DESIGN FUND IV, L.P.","type":"Company","kind":"company","jurisdiction":"US","identifier":"sec:0001680307","risk":"LOW","flags":[],"registry_profile":null},"identity":{"linked_records":[{"id":"f8aaec75-241c-5a6a-88de-fb00867ba5c9","name":"DEERFIELD PRIVATE DESIGN FUND IV, L.P.","jurisdiction":"US","identifier":"lei:549300QJOA5QI17WBG46","registry":"gleif"}],"also_known_in":["gleif"]},"ownership":{"direct_owners":[],"holdings":[{"role":"other","share":null,"subsidiary":{"id":"72e3523f-efab-5ee4-b03e-4139df749767","name":"Larimar Therapeutics, Inc.","type":"Company","kind":"company","identifier":"sec:0001374690"}},{"role":"director","share":null,"subsidiary":{"id":"72e3523f-efab-5ee4-b03e-4139df749767","name":"Larimar Therapeutics, Inc.","type":"Company","kind":"company","identifier":"sec:0001374690"}},{"role":"tenpercentowner","share":null,"subsidiary":{"id":"72e3523f-efab-5ee4-b03e-4139df749767","name":"Larimar Therapeutics, Inc.","type":"Company","kind":"company","identifier":"sec:0001374690"}},{"role":"tenpercentowner","share":null,"subsidiary":{"id":"c311f0a0-a099-557a-ba70-bfce08965197","name":"Nuvalent, Inc.","type":"Company","kind":"company","identifier":"sec:0001861560"}},{"role":"director","share":null,"subsidiary":{"id":"c311f0a0-a099-557a-ba70-bfce08965197","name":"Nuvalent, Inc.","type":"Company","kind":"company","identifier":"sec:0001861560"}},{"role":"other","share":null,"subsidiary":{"id":"c311f0a0-a099-557a-ba70-bfce08965197","name":"Nuvalent, Inc.","type":"Company","kind":"company","identifier":"sec:0001861560"}},{"role":"tenpercentowner","share":null,"subsidiary":{"id":"a9c00c55-4330-55f3-a417-febad978a7c8","name":"ARS Pharmaceuticals, Inc.","type":"Company","kind":"company","identifier":"sec:0001671858"}},{"role":"tenpercentowner","share":null,"subsidiary":{"id":"3991c58b-6e98-52ec-aa30-822af204de0b","name":"AdaptHealth Corp.","type":"Company","kind":"company","identifier":"sec:0001725255"}},{"role":"other","share":null,"subsidiary":{"id":"3991c58b-6e98-52ec-aa30-822af204de0b","name":"AdaptHealth Corp.","type":"Company","kind":"company","identifier":"sec:0001725255"}},{"role":"tenpercentownerother","share":null,"subsidiary":{"id":"a9c00c55-4330-55f3-a417-febad978a7c8","name":"ARS Pharmaceuticals, Inc.","type":"Company","kind":"company","identifier":"sec:0001671858"}},{"role":"tenpercentownerother","share":null,"subsidiary":{"id":"c311f0a0-a099-557a-ba70-bfce08965197","name":"Nuvalent, Inc.","type":"Company","kind":"company","identifier":"sec:0001861560"}},{"role":"director","share":null,"subsidiary":{"id":"a9c00c55-4330-55f3-a417-febad978a7c8","name":"ARS Pharmaceuticals, Inc.","type":"Company","kind":"company","identifier":"sec:0001671858"}},{"role":"tenpercentownerother","share":null,"subsidiary":{"id":"72e3523f-efab-5ee4-b03e-4139df749767","name":"Larimar Therapeutics, Inc.","type":"Company","kind":"company","identifier":"sec:0001374690"}},{"role":"tenpercentownerother","share":null,"subsidiary":{"id":"a485ead8-2cff-5533-b09d-c62eabdf701d","name":"Mirum Pharmaceuticals, Inc.","type":"Company","kind":"company","identifier":"sec:0001759425"}},{"role":"tenpercentownerother","share":null,"subsidiary":{"id":"4fb4cbe0-0cf8-5556-b28c-8f0b5f7d4eb6","name":"Oncology Institute, Inc.","type":"Company","kind":"company","identifier":"sec:0001799191"}},{"role":"tenpercentownerother","share":null,"subsidiary":{"id":"bf67dc53-807a-500f-904c-d1c0a83a310e","name":"Singular Genomics Systems, Inc.","type":"Company","kind":"company","identifier":"sec:0001850906"}},{"role":"tenpercentownerother","share":null,"subsidiary":{"id":"8a5e122d-7278-5f7d-88fd-4cc49f252dff","name":"Edgewise Therapeutics, Inc.","type":"Company","kind":"company","identifier":"sec:0001710072"}},{"role":"tenpercentownerother","share":null,"subsidiary":{"id":"ea2cc909-5d92-5fdb-931f-208c65007c96","name":"Annexon, Inc.","type":"Company","kind":"company","identifier":"sec:0001528115"}},{"role":"tenpercentownerother","share":null,"subsidiary":{"id":"3ebe47b2-1755-5682-a49d-3331c6f8189a","name":"Nkarta, Inc.","type":"Company","kind":"company","identifier":"sec:0001787400"}},{"role":"director","share":null,"subsidiary":{"id":"4fb4cbe0-0cf8-5556-b28c-8f0b5f7d4eb6","name":"Oncology Institute, Inc.","type":"Company","kind":"company","identifier":"sec:0001799191"}},{"role":"tenpercentownerother","share":null,"subsidiary":{"id":"97df95ba-afe9-514a-8d91-52dfbd0319dd","name":"Schrodinger, Inc.","type":"Company","kind":"company","identifier":"sec:0001490978"}},{"role":"tenpercentownerother","share":null,"subsidiary":{"id":"69f58bea-eda5-5fda-9043-f7c5d5abebe9","name":"Revolution Medicines, Inc.","type":"Company","kind":"company","identifier":"sec:0001628171"}},{"role":"tenpercentownerother","share":null,"subsidiary":{"id":"ef30717a-59f7-5bee-82f2-b231ba7e9927","name":"Cabaletta Bio, Inc.","type":"Company","kind":"company","identifier":"sec:0001759138"}},{"role":"tenpercentownerother","share":null,"subsidiary":{"id":"71e9bcfd-4176-551b-b776-01b734a2fd82","name":"Korro Bio, Inc.","type":"Company","kind":"company","identifier":"sec:0001703647"}},{"role":"director","share":null,"subsidiary":{"id":"3991c58b-6e98-52ec-aa30-822af204de0b","name":"AdaptHealth Corp.","type":"Company","kind":"company","identifier":"sec:0001725255"}},{"role":"tenpercentownerother","share":null,"subsidiary":{"id":"3991c58b-6e98-52ec-aa30-822af204de0b","name":"AdaptHealth Corp.","type":"Company","kind":"company","identifier":"sec:0001725255"}},{"role":"tenpercentownerother","share":null,"subsidiary":{"id":"c68c871a-7d56-5616-92f8-6e15a2da829d","name":"ARVINAS, INC.","type":"Company","kind":"company","identifier":"sec:0001655759"}},{"role":"directorother","share":null,"subsidiary":{"id":"d54e2413-cebc-5e01-bc86-3b7d84bd9785","name":"Protara Therapeutics, Inc.","type":"Company","kind":"company","identifier":"sec:0001359931"}}],"ubo_chain":[]},"risk":{"level":"LOW","flags":[],"note":"Risk is a layer-1 signal (offshore-layering / connectivity heuristics) — an investigative lead, not a determination."},"financials":null,"sources":[],"access":{"tier":"free","note":"Free tier: identity, cross-source links, 1-hop subsidiaries, risk/sanctions, latest financials and provenance. The full multi-hop UBO chain, itemised assets (vessels/aircraft/securities/real estate) and financial history unlock with a paid API key or a one-off dossier — whiteintel.dev/pricing."},"source":"corpus"}